KROS Q1 2023 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$36M

EPS (Diluted)

$-1.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$384M

Total Liabilities

$29M

Stockholders' Equity

$355M

Cash & Equivalents

$351M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$24M	-61.1%
Net Income	-$36M	-$24M	-48.0%

Revenue Segments

License

$144M100%